A molecule designed by generative AI is now in a Phase III trial. That is a genuine milestone, and the detail that matters is what it did not replace.
Key takeaways
- Insilico Medicine launched a Phase III programme in July 2026 for rentosertib, a potentially first-in-class oral small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis, discovered.
- 87 live listings in this category publish a rate, at a median top-of-range of $100 an hour and a ceiling of $230.
- The work is remote contract work, asynchronous, with no set hours and no guaranteed volume.
- Applications screen on a short skills assessment rather than a resume or interview.
What was reported
The finding
Insilico Medicine launched a Phase III programme in July 2026 for rentosertib, a potentially first-in-class oral small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis, discovered and designed using its Pharma.AI platform combining the PandaOmics biology engine and Chemistry42 generative chemistry. The randomised, double-blind, placebo-controlled Phase III study is expected to enrol 320 patients across 47 centres in China. The GENESIS-IPF Phase IIa study showed manageable safety and tolerability, with the 60 mg once-daily arm showing mean forced vital capacity improvement of 98.4 mL at 12 weeks. The programme has been published in Nature Biotechnology, Nature Medicine and the Journal of Medicinal Chemistry.
Rentosertib came from Insilico's Pharma.AI platform: an AI-prioritised target from PandaOmics, a generatively designed molecule from Chemistry42. From there it went through preclinical fibrosis biology, Phase 0, Phase I human safety, and a randomised Phase IIa that showed mean forced vital capacity improvement of 98.4 mL at 12 weeks on 60 mg once daily. Phase III will enrol 320 patients across 47 centres, published along the way in Nature Biotechnology, Nature Medicine and the Journal of Medicinal Chemistry.
What the listings pay
AI compressed discovery. It did not touch validation. Every human safety and efficacy question was answered the conventional way, by people who design and interpret trials.
| # | Role | Advertised rate | Platform |
|---|---|---|---|
| 1 | Disease-Area Clinician, Trial Endpoints & Prescribing | $150 to $230 an hour | Mercor |
| 2 | Structural Biologist (Protein Design, AI Evaluation) | $150 to $220 an hour | Mercor |
| 3 | Pharma Commercial Forecasting Expert, Launch Curves | $130 to $210 an hour | Mercor |
| 4 | Therapeutic Area & Clinical Survey Expert | $200 to $200 an hour | Mercor |
| 5 | Clinician (Oncology / Hematology) | $160 to $200 an hour | micro1 |
| 6 | Biotech Investment Analyst, Drug Asset & Company Assessment | $120 to $200 an hour | Mercor |
| 7 | Multilingual Primary Care Physician (MD): Clinical Documentation & AI Evaluation | $170 to $190 an hour | Mercor |
| 8 | Medical Safety Expert | $140 to $190 an hour | Mercor |
| 9 | Clinical Law Professor / Clinic Director | $180 to $180 an hour | Mercor |
| 10 | Multilingual Inpatient Hospitalist (MD): Clinical Documentation & AI Evaluation | $170 to $170 an hour | Mercor |
Source: 87 live listings on this board that publish a rate, read directly from each posting on 2026-09-06. Listings without a published rate are excluded rather than estimated.
How this compares across the board
A rate only means something next to the alternatives. This is every category we track with at least five listings publishing a rate, ranked by median top-of-range, so you can see where this work sits rather than taking a single number on trust.
| Category | Listings | Median low | Median top | Highest |
|---|---|---|---|---|
| Legal | 95 | $100 | $140 | $400 |
| Medical | 68 | $77 | $120 | $400 |
| Consulting | 45 | $80 | $120 | $280 |
| Finance | 94 | $80 | $110 | $280 |
| Engineering | 114 | $70 | $100 | $300 |
| Research/PhD | 132 | $70 | $90 | $280 |
| Writing | 36 | $40 | $80 | $280 |
| Bilingual | 78 | $44 | $52 | $120 |
| Annotation | 25 | $12 | $24 | $120 |
Same source and date as above. Categories are matched on listing title, so a role can appear in more than one.
What it means for you
That is the expertise being bought. Across 87 live pharmacology, clinical and biomedical listings on our board that publish a rate, the median top-of-range is $100 an hour, reaching $230. See pharmacologist roles.
Who should apply
Two checks before you spend time on an application. Confirm the role accepts applicants from your country with the eligibility checker, since a meaningful share of listings carry location requirements. Then run the advertised rate through the take-home calculator, because this is contract work and the headline figure is before self-employment tax.
Applications complete on the hiring platform and usually take a few minutes, with a short skills assessment in place of an interview. Fill in every credential, language and professional background field on your profile. Those are what route you to the better paid listings, and most applicants leave them blank.
Frequently asked questions
What is rentosertib?
A potentially first-in-class oral small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis, discovered and designed using Insilico's Pharma.AI platform.
What did the AI actually do?
It prioritised the biological target via PandaOmics and generatively designed the molecule via Chemistry42. Preclinical and clinical validation were conventional.
How strong is the evidence so far?
The Phase IIa GENESIS-IPF study showed manageable safety and tolerability, with the 60 mg once-daily arm showing mean forced vital capacity improvement of 98.4 mL at 12 weeks. Phase III will enrol 320 patients across 47 centres.
What does pharmacology AI work pay?
Across 87 live pharmacology and biomedical listings publishing a rate, the median top-of-range is $100 an hour, reaching $230.
Does AI drug discovery reduce demand for pharmacologists?
So far the opposite. Compressing discovery increases the number of candidates needing rigorous human validation, which is where the paid expertise sits.
Sources
See every live role
The full board updates several times a week, with the advertised rate on each listing and closed roles removed.